

PTO/SB/08a/s (08-03)

Approved for use through 07/31/2006 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/601,020
		Filing Date	June 20, 2003
		First Named Inventor	Andrea D Branch, et al.
		Art Unit	1648
		Examiner Name	Timothy M. Brown
Sheet 1 of 2	Attorney Docket Number	RII-003CPUSDV1	

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ² -Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

¹EXAMINER (initials) if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinda Codes or USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁷Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
AB	B1	Boulant, S., et al. "Unusual multiple recoding events leading to alternative forms of hepatitis C virus core protein from Genotype 1b." <i>J Biol Chem.</i> 2003 Nov 14; 278(46):45785-92			
AB	B2	Branch, A D., et al. "The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others." <i>Semin Liver Dis.</i> 2005 Feb; 25(1):105-17			
AB	B3	Choi, J., et al. "Triple decoding of hepatitis C virus RNA by programmed translational frameshifting." <i>Mol Cell Biol.</i> 2003 Mar; 23(5):1489-97.			
AB	B4	Komurian-Pradel, F., et al. "Antigenic relevance of F protein in chronic hepatitis C virus infection." <i>Hepatology.</i> 2004 Oct; 40(4):900-9			
AB	B5	Ogata, S., et al. "Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma." <i>J Clin Microbiol.</i> 2002 Oct; 40(10):3625-30.			
AB	B6	Rodriguez-Lopes, M. "Immunogenicity of variable regions of hepatitis C proteins." <i>Journ. Of Gen. Virol.</i> 1999; 80:727-73.			
AB	B7	Roussel, J., et al. "Characterization of the expression of the Hepatitis C virus F protein." <i>J Virol.</i> 2003; 84:1751-1759			
AB	B8	Tan, S-L., et al. "Hepatitis C therapeutics: current status and emerging strategies." <i>Nature</i> 2002 Nov; 1:867-881			
AB	B9	Vassilaki, N., et al. "Two alternative translation mechanisms are responsible for the expression of the HCV ARF/F/Core +1 coding open reading frame." <i>J Biol Chem.</i> 2003 Oct; 278:40503-40513.			

Examiner Signature	/Agnieszka Boesen/	Date Considered	09/07/2006
--------------------	--------------------	-----------------	------------

PTO/SB/088/0 (08-03)
 Approved for use through 07/31/2008 OMB 0651-0031
 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/601,020
		Filing Date	June 20, 2003
		First Named Inventor	Andrea D. Branch, et al
		Art Unit	1648
		Examiner Name	Timothy M. Brown
		Attorney Docket Number	R11-003CPUSDV1
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T ²
AB	C1	Walewski, J.L., et al. "Reading between the lines: evidence for a new Hepatitis C virus protein." <i>Hepatology</i> , 2003 Sep, 36(3) 757-60	
AB	C2	Walewski, J.L., et al. "Mutation Master profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions." <i>RNA</i> , 2002 May, 8(5) 557-71	
AB	C3	Walewski, J.L., et al. "Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame." <i>RNA</i> , 2001 May, 7(5) 710-21.	
AB	C4	Walewski, J.L., et al. "HCV patients have antibodies against a novel protein encoded in a second reading frame." <i>Hepatology</i> 28 (4, Pt. 2):278A, Abstr. 462 (October 1998).	
AB	C5	Xu, Z., et al. "Hepatitis C virus F protein is a short-lived protein associated with the endoplasmic reticulum." <i>J Virol</i> , 2003 Jan, 77(2):1578-83.	
AB	C6	Yeh, C-T, et al. "Amino acid substitutions in codons 9-11 of hepatitis C virus core protein lead to the synthesis of a short core protein product." <i>J Gastroenterol Hepatol</i> , 2000 Feb, 15(2) 182-91	

¹EXAMINER: (Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Agnieszka Boesen/	Date Considered	09/07/2006
--------------------	--------------------	-----------------	------------



APPLICANT FACSIMILE OF FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO R11-003CPUSCN	SERIAL NO. 10/601020
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)			APPLICANT Branch, Andrea D. et al.	
			FILING DATE June 20, 2003	GROUP 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AB	A1	5,350,671	09/94	Houghton <i>et al.</i>	435	5	
AB	A2	5,443,965	08/95	Reyes <i>et al.</i>	435	693	
AB	A3	5,728,520	03/98	Weiner <i>et al.</i>	435	5	
AB	A4	5,840,839	11/98	Wang <i>et al.</i>	530	325	
AB	A5	6,027,729	02/00	Houghton <i>et al.</i>	424	228.1	
AB	A6	6,054,264	04/00	Chien <i>et al.</i>	435	5	
AB	A7	6,074,846	06/00	Ralston <i>et al.</i>	435	69.3	
AB	A8	6,150,087	11/00	Chien	435	5	
AB	A9	6,171,782	01/01	Houghton <i>et al.</i>	435	5	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
AB	A10	WO 94/25601 A2,A3	11/94	WO				
AB	A11	WO 96/05315 A2,A3	02/96	WO				
AB	A12	WO 96/40227 A1	12/96	WO				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

AB	A13	Bullock, T.N.J. <i>et al.</i> "Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames," <i>J. Exp. Med.</i> , 184:1319-29 (1996).
AB	A14	Feucht, H.-H. <i>et al.</i> "Study on Reliability of Commercially Available Hepatitis C Virus Antibody Tests" <i>Journal of Clinical Microbiology</i> 33(3):620-624 (March 1995).
AB	A15	Ina, Y. <i>et al.</i> "Reduction of synonymous substitutions in the core protein gene of hepatitis C virus," <i>J. Mol. Evol.</i> , 38:50-56 (1994).
AB	A16	Lo, S.-Y. <i>et al.</i> "Comparative studies of the core gene products of two different hepatitis C virus isolates: two alternative forms determined by a single amino acid substitution." <i>Virology</i> 199(1):124-31(1994 Feb. 15).
AB	A17	Lo, S.-Y. <i>et al.</i> "Differential subcellular localization of hepatitis C virus core gene products." <i>Virology</i> 213(2):455-61(1995 Nov. 10).
AB	A18	Lo, S.-Y. <i>et al.</i> "Interaction between hepatitis C virus core protein and E1 envelope protein." <i>J. Virol.</i> 70(8):5177-82 (1996 Aug.).
AB	A19	Malarkannan, S. <i>et al.</i> "Presentation of out-of-frame peptide/MHC class I complexes by a novel translation initiation mechanism." <i>Immunity</i> 10(6):681-90 (1999 Jun.).
AB	A20	Ray, B.R. <i>et al.</i> "Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype." <i>J. Virol.</i> 70(7):4438-43 (1996 Jul).

Examiner /Agnieszka Boesen/	Date Considered 09/07/2006
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SERIAL NO.

Sheet 2 of 2

R11-003CPUSCN

10/601020

APPLICANT

Branch, Andrea D. et al.

FILING DATE

June 20, 2003

GROUP

1648

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

Examiner

/Agnieszka Boesen/

Date Considered

09/07/2006

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.